LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 19

Search options

  1. Article ; Online: Current Desensitization Strategies in Heart Transplantation.

    Habal, Marlena V

    Frontiers in immunology

    2021  Volume 12, Page(s) 702186

    Abstract: Heart transplant candidates sensitized to HLA antigens wait longer for transplant, are at increased risk of dying while waiting, and may not be listed at all. The increasing prevalence of HLA sensitization and limitations of current desensitization ... ...

    Abstract Heart transplant candidates sensitized to HLA antigens wait longer for transplant, are at increased risk of dying while waiting, and may not be listed at all. The increasing prevalence of HLA sensitization and limitations of current desensitization strategies underscore the urgent need for a more effective approach. In addition to pregnancy, prior transplant, and transfusions, patients with end-stage heart failure are burdened with unique factors placing them at risk for HLA sensitization. These include homograft material used for congenital heart disease repair and left ventricular assist devices (LVADs). Moreover, these risks are often stacked, forming a seemingly insurmountable barrier in some cases. While desensitization protocols are typically implemented uniformly, irrespective of the mode of sensitization, the heterogeneity in success and post-transplant outcomes argues for a more tailored approach. Achieving this will require progress in our understanding of the immunobiology underlying the innate and adaptive immune response to these varied allosensitizing exposures. Further attention to B cell activation, memory, and plasma cell differentiation is required to establish methods that durably abrogate the anti-HLA antibody response before and after transplant. The contribution of non-HLA antibodies to the net state of sensitization and the potential implications for graft longevity also remain to be comprehensively defined. The aim of this review is to first bring forth select issues unique to the sensitized heart transplant candidate. The current literature on desensitization in heart transplantation will then be summarized providing context within the immune response. Building on this, newer approaches with therapeutic potential will be discussed emphasizing the importance of not only addressing the short-term pathogenic consequences of circulating HLA antibodies, but also the need to modulate alloimmune memory.
    MeSH term(s) Female ; HLA Antigens/immunology ; Heart Transplantation/methods ; Histocompatibility/immunology ; Humans ; Male ; Transplantation Immunology/immunology
    Chemical Substances HLA Antigens
    Language English
    Publishing date 2021-08-24
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2021.702186
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: From bench to bedside: reversing established antibody responses and desensitization.

    Chong, Anita S / Habal, Marlena V

    Current opinion in organ transplantation

    2022  Volume 27, Issue 5, Page(s) 376–384

    Abstract: Purpose of review: Basic transplant immunology has primarily focused on the definition of mechanisms, but an often-stated aspirational goal is to translate basic mechanistic research into future therapy. Pretransplant donor-specific antibodies (DSA) ... ...

    Abstract Purpose of review: Basic transplant immunology has primarily focused on the definition of mechanisms, but an often-stated aspirational goal is to translate basic mechanistic research into future therapy. Pretransplant donor-specific antibodies (DSA) mediate hyperacute as well as early antibody-mediated rejection (AMR), whereas DSA developing late posttransplantation may additionally mediate chronic rejection. Although contemporary immunosuppression effectively prevents early cellular rejection after transplant in nonsensitized patients, it is less effective at controlling preexisting HLA antibody responses or reversing DSA once established, thus underscoring a need for better therapies.
    Recent findings: We here review the development of a bench-to-bedside approach involving transient proteasome inhibition to deplete plasma cells, combined with maintenance co-stimulation blockade, with CTLA-4Ig or belatacept, to prevent the generation of new antibody-secreting cells (ASCs).
    Summary: This review discusses how this treatment regimen, which was rationally designed and validated to reverse established DSA responses in mouse models, translated into reversing active AMR in the clinic, as well as desensitizing highly sensitized patients on the transplant waitlist.
    MeSH term(s) Animals ; Antibody Formation ; Graft Rejection ; HLA Antigens ; Humans ; Isoantibodies ; Kidney Transplantation/adverse effects ; Mice
    Chemical Substances HLA Antigens ; Isoantibodies
    Language English
    Publishing date 2022-08-03
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 1390429-2
    ISSN 1531-7013 ; 1087-2418
    ISSN (online) 1531-7013
    ISSN 1087-2418
    DOI 10.1097/MOT.0000000000001009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Long-term management of end-stage heart failure.

    Habal, Marlena V / Garan, A Reshad

    Best practice & research. Clinical anaesthesiology

    2017  Volume 31, Issue 2, Page(s) 153–166

    Abstract: End-stage heart failure manifests as severe and often relentless symptoms that define the clinical syndrome of heart failure, namely congestion and hypoperfusion. These patients suffer from dyspnea, fatigue, abdominal discomfort, and ultimately cardiac ... ...

    Abstract End-stage heart failure manifests as severe and often relentless symptoms that define the clinical syndrome of heart failure, namely congestion and hypoperfusion. These patients suffer from dyspnea, fatigue, abdominal discomfort, and ultimately cardiac cachexia. Renal and hepatic dysfunction frequently further complicates the process. Recurrent hospitalizations, cardiac arrhythmias, and intolerance to standard heart failure therapies are common as the disease progresses. Management focuses on controlling symptoms, correcting precipitants, avoiding triggers, and maximizing therapies with demonstrable survival benefit. Among appropriate candidates, advanced therapies such as orthotopic heart transplant (OHT) can significantly extend survival and improve the quality of life. Left ventricular assist devices have been used with increasing frequency as a bridge to OHT or as a destination therapy in appropriately selected candidates where they have a demonstrable mortality benefit over medical therapy. Importantly, a multidisciplinary patient-centered approach is crucial when considering these advanced therapies.
    MeSH term(s) Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Cardiac Resynchronization Therapy/trends ; Disease Management ; Heart Failure/diagnosis ; Heart Failure/physiopathology ; Heart Failure/therapy ; Heart Transplantation/methods ; Heart Transplantation/trends ; Heart-Assist Devices/trends ; Humans ; Palliative Care/methods ; Palliative Care/trends ; Time Factors
    Chemical Substances Angiotensin-Converting Enzyme Inhibitors
    Language English
    Publishing date 2017-06
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2028818-9
    ISSN 1878-1608 ; 1521-6896 ; 1753-3740
    ISSN (online) 1878-1608 ; 1521-6896
    ISSN 1753-3740
    DOI 10.1016/j.bpa.2017.07.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Advanced Therapies for Advanced Heart Failure in Women.

    Habal, Marlena V / Axsom, Kelly / Farr, Maryjane

    Heart failure clinics

    2018  Volume 15, Issue 1, Page(s) 97–107

    Abstract: Women with advanced heart failure (HF) are underrepresented in trials of short-term and durable mechanical circulatory support although they derive similar benefit. In acute HF, intensive medical and interventional therapies are effective but ... ...

    Abstract Women with advanced heart failure (HF) are underrepresented in trials of short-term and durable mechanical circulatory support although they derive similar benefit. In acute HF, intensive medical and interventional therapies are effective but underutilized. The smaller, newer generation, left ventricular assist devices (LVADs) have increased the feasibility of durable support in women. Women frequently present late, with more comorbidities, emphasizing the need for timely referral. Compared with men, the stroke risk is higher in women with an LVAD. Increased representation in clinical trials and a better understanding of the psychosocial issues affecting women is essential.
    MeSH term(s) Assisted Circulation/instrumentation ; Assisted Circulation/methods ; Disease Progression ; Female ; Heart Failure/physiopathology ; Heart Failure/therapy ; Heart-Assist Devices/classification ; Heart-Assist Devices/trends ; Humans ; Male ; Needs Assessment ; Sex Factors ; Treatment Outcome
    Language English
    Publishing date 2018-10-24
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2212019-1
    ISSN 1551-7136
    ISSN 1551-7136
    DOI 10.1016/j.hfc.2018.08.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Desensitization in the Era of Precision Medicine: Moving From the Bench to Bedside.

    Habal, Marlena V / Farr, Maryjane / Restaino, Susan / Chong, Anita

    Transplantation

    2019  Volume 103, Issue 8, Page(s) 1574–1581

    Abstract: Patients with antibodies to HLA wait longer for transplant and are at increased risk of adverse outcomes. For more than a decade, drug therapy approaches have been tested to modulate the immune system to prevent or reduce donor-specific antibody levels. ... ...

    Abstract Patients with antibodies to HLA wait longer for transplant and are at increased risk of adverse outcomes. For more than a decade, drug therapy approaches have been tested to modulate the immune system to prevent or reduce donor-specific antibody levels. Despite some studies reporting success in facilitating transplant, many patients do not respond or experience donor-specific antibody rebound, highlighting the diversity of the individual patient's immune response. While advances in immunomodulatory therapies have resulted in escalating efforts to successfully treat highly sensitized patients, further insight into the human immune system has uncovered its enormous complexity and diversity calling for a personalized approach. Yet, even defining the sensitized transplant candidate can be troublesome and much remains to be understood about the interaction between an individual's immune system as a whole and their response to our current desensitization strategies. The shift toward a personalized approach calls for a reevaluation of what we know and what remains to be determined; a process that will require iterative translational approaches. This review will focus on new insights into how the interaction between immune risk assessment, the patient's immunological history, and the clinical context can be reconciled to develop a precision-based approach to pretransplant management.
    MeSH term(s) Autoimmunity ; Desensitization, Immunologic/methods ; Graft Rejection/immunology ; Graft Rejection/prevention & control ; Graft Survival ; HLA Antigens/immunology ; Humans ; Isoantibodies/immunology ; Kidney Transplantation ; Precision Medicine/methods
    Chemical Substances HLA Antigens ; Isoantibodies
    Language English
    Publishing date 2019-07-05
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    DOI 10.1097/TP.0000000000002737
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Impact of Pretransplant Malignancy on Heart Transplantation Outcomes: Contemporary United Network for Organ Sharing Analysis Amidst Evolving Cancer Therapies.

    Batra, Jaya / DeFilippis, Ersilia M / Golob, Stephanie / Clerkin, Kevin / Topkara, Veli K / Habal, Marlena V / Restaino, Susan / Griffin, Jan / Hi Lee, Sun / Latif, Farhana / Farr, Maryjane A / Sayer, Gabriel / Raikelkar, Jayant / Uriel, Nir

    Circulation. Heart failure

    2022  Volume 15, Issue 4, Page(s) e008968

    Abstract: Background: An aging population and improved cancer survivorship have increased the number of individuals with treated malignancy who develop advanced heart failure. The benefits of heart transplantation (HT) in patients with a pretransplant malignancy ( ...

    Abstract Background: An aging population and improved cancer survivorship have increased the number of individuals with treated malignancy who develop advanced heart failure. The benefits of heart transplantation (HT) in patients with a pretransplant malignancy (PTM) must be balanced against risks of posttransplant malignancy in the setting of immunosuppression.
    Methods: Adult patients in the United Network for Organ Sharing registry who received HT between January 1, 2010, and December 31, 2020 were included. Trends, patient characteristics, and posttransplant outcomes in HT recipients with PTM were evaluated.
    Results: From 2000 to 2020, the proportion of HT recipients with PTM increased from 3.2% to 8.2%. From 2010 to 2020, 2113 (7.7%) of 27 344 HT recipients had PTM. PTM was associated with higher rates of 1-year mortality after HT (11.9% versus 9.2%; adjusted hazard ratio, 1.25 [95% CI, 1.09-1.44],
    Conclusions: Prevalence of PTM in HT recipients nearly tripled over the past 2 decades. Patients with hematologic PTM were at increased risk of early mortality after HT. Patients with PTM were also at higher risk for posttransplant malignancy. Guidelines that reflect contemporary oncological care are needed to inform care of this heterogenous and expanding group of individuals.
    MeSH term(s) Adult ; Aged ; Heart Failure/complications ; Heart Failure/surgery ; Heart Transplantation/adverse effects ; Humans ; Neoplasms/epidemiology ; Proportional Hazards Models ; Registries ; Retrospective Studies ; United States/epidemiology
    Language English
    Publishing date 2022-01-31
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2429459-7
    ISSN 1941-3297 ; 1941-3289
    ISSN (online) 1941-3297
    ISSN 1941-3289
    DOI 10.1161/CIRCHEARTFAILURE.121.008968
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis.

    Jennings, Douglas L / Sultan, Lina / Mingov, Jennifer / Choe, Jason / Latif, Farhana / Restaino, Susan / Clerkin, Kevin / Habal, Marlena V / Colombo, Paolo C / Yuzefpulskaya, Melana / Sayer, Gabriel / Uriel, Nir / Baker, William L

    Heart failure reviews

    2022  Volume 28, Issue 1, Page(s) 149–156

    Abstract: Coronary allograft vasculopathy (CAV) continues to afflict a high number of heart transplant (HT) recipients, and elevated LDL is a key risk factor. Many patients cannot tolerate statin medications after HT; however, data for alternative agents remains ... ...

    Abstract Coronary allograft vasculopathy (CAV) continues to afflict a high number of heart transplant (HT) recipients, and elevated LDL is a key risk factor. Many patients cannot tolerate statin medications after HT; however, data for alternative agents remains scarce. To address this key evidence gap, we evaluated the safety and efficacy of the PCSK9i after HT through systematic review and meta-analysis. We searched Medline, Cochrane Central, and Scopus from the earliest date through July 15th, 2021. Citations were included if they were a report of PCSK9i use in adults after HT and reported an outcome of interest. Outcomes included change in LDL cholesterol from baseline, incidence of adverse events, and evidence of CAV. Changes from baseline and outcome incidences were pooled using contemporary random-effects model methodologies. A total of six studies including 97 patients were included. Over a mean follow-up of 13 months (range 3-21), PCSK9i use lowered LDL by 82.61 mg/dL (95% CI - 119.15 to - 46.07; I
    MeSH term(s) Adult ; Humans ; Heart Transplantation ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; PCSK9 Inhibitors/therapeutic use ; Cholesterol, LDL
    Chemical Substances Hydroxymethylglutaryl-CoA Reductase Inhibitors ; PCSK9 Inhibitors ; Cholesterol, LDL
    Language English
    Publishing date 2022-06-10
    Publishing country United States
    Document type Meta-Analysis ; Systematic Review ; Journal Article ; Review
    ZDB-ID 1336499-6
    ISSN 1573-7322 ; 1382-4147
    ISSN (online) 1573-7322
    ISSN 1382-4147
    DOI 10.1007/s10741-022-10255-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019.

    Latif, Farhana / Farr, Maryjane A / Clerkin, Kevin J / Habal, Marlena V / Takeda, Koji / Naka, Yoshifumi / Restaino, Susan / Sayer, Gabriel / Uriel, Nir

    JAMA cardiology

    2020  Volume 5, Issue 10, Page(s) 1165–1169

    Abstract: Importance: Recipients of heart transplant (HT) may be at increased risk of adverse outcomes attributable to infection with coronavirus disease 2019 (COVID-19) because of multiple comorbidities and clinically significant immunosuppression.: Objective!# ...

    Abstract Importance: Recipients of heart transplant (HT) may be at increased risk of adverse outcomes attributable to infection with coronavirus disease 2019 (COVID-19) because of multiple comorbidities and clinically significant immunosuppression.
    Objective: To describe the characteristics, treatment, and outcomes of recipients of HT with COVID-19.
    Design, setting, and participants: This case series from a single large academic heart transplant program in New York, New York, incorporates data from between March 1, 2020, and April 24, 2020. All recipients of HT followed up by this center who were infected with COVID-19 were included.
    Interventions: Heart transplant and a confirmed diagnosis of COVID-19.
    Main outcomes and measures: The primary measure was vital status at end of study follow-up. Secondary measures included patient characteristics, laboratory analyses, changes to immunosuppression, and treatment administered for COVID-19.
    Results: Twenty-eight patients with HT received a confirmed diagnosis of COVID-19. The median age was 64.0 (interquartile range [IQR], 53.5-70.5) years, 22 (79%) were men, and the median time from HT was 8.6 (IQR, 4.2-14.5) years. Comorbid conditions included hypertension in 20 patients (71%), diabetes in 17 patients (61%), and cardiac allograft vasculopathy in 16 patients (57%). Twenty-two participants (79%) were admitted for treatment, and 7 (25%) required mechanical ventilation. Most (13 of 17 [76%]) had evidence of myocardial injury (median high-sensitivity troponin T, 0.055 [IQR, 0.0205-0.1345] ng/mL) and elevated inflammatory biomarkers (median peak high-sensitivity C-reactive protein, 11.83 [IQR, 7.44-19.26] mg/dL; median peak interleukin 6, 105 [IQR, 38-296] pg/mL). Among patients managed at the study institution, mycophenolate mofetil was discontinued in 16 patients (70%), and 6 (26%) had a reduction in the dose of their calcineurin inhibitor. Treatment of COVID-19 included hydroxychloroquine (18 patients [78%]), high-dose corticosteroids (8 patients [47%]), and interleukin 6 receptor antagonists (6 patients [26%]). Overall, 7 patients (25%) died. Among 22 patients (79%) who were admitted, 11 (50%) were discharged home, 4 (18%) remain hospitalized at the end of the study, and 7 (32%) died during hospitalization.
    Conclusions and relevance: In this single-center case series, COVID-19 infection was associated with a case fatality rate of 25% in recipients of HT. Immunosuppression was reduced in most of this group of patients. Further study is required to evaluate the optimal approach to management of COVID-19 infection in the HT population.
    MeSH term(s) Aged ; Biomarkers/blood ; C-Reactive Protein/analysis ; COVID-19/mortality ; COVID-19/therapy ; Comorbidity ; Female ; Glucocorticoids/therapeutic use ; Heart Transplantation ; Hospitalization/statistics & numerical data ; Humans ; Hydroxychloroquine/therapeutic use ; Immunosuppressive Agents/administration & dosage ; Interleukin-6/blood ; Male ; Middle Aged ; New York City/epidemiology ; Receptors, Interleukin-6/antagonists & inhibitors ; Respiration, Artificial/statistics & numerical data ; Retrospective Studies ; Transplant Recipients ; Troponin T/blood
    Chemical Substances Biomarkers ; Glucocorticoids ; Immunosuppressive Agents ; Interleukin-6 ; Receptors, Interleukin-6 ; Troponin T ; Hydroxychloroquine (4QWG6N8QKH) ; C-Reactive Protein (9007-41-4)
    Keywords covid19
    Language English
    Publishing date 2020-05-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ISSN 2380-6591
    ISSN (online) 2380-6591
    DOI 10.1001/jamacardio.2020.2159
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Heart rate in patients with reduced ejection fraction: relationship between single time point measurement and mean heart rate on prolonged implantable cardioverter defibrillator monitoring.

    Habal, Marlena V / Nanthakumar, Kumaraswamy / Austin, Peter C / Freitas, Cassandra / Labos, Christopher / Lee, Douglas S

    BMC cardiovascular disorders

    2018  Volume 18, Issue 1, Page(s) 17

    Abstract: Background: Heart rate (HR) is a prognostic marker that is increasingly used as a therapeutic target in patients with cardiovascular disease. The association between resting and mean HR remains unclear. We therefore set out to determine the relationship ...

    Abstract Background: Heart rate (HR) is a prognostic marker that is increasingly used as a therapeutic target in patients with cardiovascular disease. The association between resting and mean HR remains unclear. We therefore set out to determine the relationship between resting HR on the electrocardiogram (ECG) obtained at a single time point, and mean HR on implantable cardioverter defibrillator (ICD) interrogation amongst patients with a reduced left ventricular ejection fraction (LVEF).
    Methods: Prospective ICD data were obtained from 54 patients with LVEF < 40%. Mean HR determined using the ICD HR histograms was compared with resting HR measured on the ECG performed in the clinic.
    Results: Average resting and ICD mean HRs were 67.9 ± 10.1 and 67.8 ± 9.6 bpm respectively. There was good correlation in the overall cohort (r = 0.79), in those with resting ECG HRs ≤ 70 bpm (r = 0.62), and amongst the 27 patients on intermediate-to-high dose beta-blockers (r = 0.91). However, Bland-Altman analysis demonstrated wide limits of agreement in the overall cohort (- 12.5, 12.7 bpm), at resting HRs ≤ 70 bpm (- 12.7, 9.8 bpm), and on intermediate-to-high dose beta-blockers (- 8.9, 7.4 bpm). Moreover, resting HR did not predict the 10-bpm interval where the most time was spent.
    Conclusions: While resting HR correlated with mean HR in patients with reduced LVEF, and in important subgroups, the limits of agreement were unacceptably wide raising concern over the use of single time point resting HR as a therapeutic target.
    MeSH term(s) Aged ; Defibrillators, Implantable ; Electric Countershock/instrumentation ; Electrocardiography ; Female ; Heart Rate ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Prospective Studies ; Reproducibility of Results ; Signal Processing, Computer-Assisted ; Stroke Volume ; Time Factors ; Treatment Outcome ; Ventricular Dysfunction, Left/diagnosis ; Ventricular Dysfunction, Left/physiopathology ; Ventricular Dysfunction, Left/therapy ; Ventricular Function, Left
    Language English
    Publishing date 2018--31
    Publishing country England
    Document type Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2059859-2
    ISSN 1471-2261 ; 1471-2261
    ISSN (online) 1471-2261
    ISSN 1471-2261
    DOI 10.1186/s12872-018-0751-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Extracorporeal photopheresis and its role in heart transplant rejection: prophylaxis and treatment.

    Slomovich, Sharon / Bell, Jennifer / Clerkin, Kevin J / Habal, Marlena V / Griffin, Jan M / Raikhelkar, Jayant K / Fried, Justin A / Vossoughi, Sarah R / Finnigan, Katie / Latif, Farhana / Farr, Maryjane A / Sayer, Gabriel T / Uriel, Nir

    Clinical transplantation

    2021  Volume 35, Issue 7, Page(s) e14333

    Abstract: Heart transplantation is the gold standard therapeutic option for select patients with end-stage heart failure. Unfortunately, successful long-term outcomes of heart transplantation can be hindered by immune-mediated rejection of the cardiac allograft, ... ...

    Abstract Heart transplantation is the gold standard therapeutic option for select patients with end-stage heart failure. Unfortunately, successful long-term outcomes of heart transplantation can be hindered by immune-mediated rejection of the cardiac allograft, specifically acute cellular rejection, antibody-mediated rejection, and cardiac allograft vasculopathy. Extracorporeal photopheresis is a cellular immunotherapy that involves the collection and treatment of white blood cells contained in the buffy coat with a photoactive psoralen compound, 8-methoxy psoralen, and subsequent irradiation with ultraviolet A light. This process is thought to cause DNA and RNA crosslinking, ultimately leading to cell destruction. The true mechanism of therapeutic action remains unknown. In the last three decades, extracorporeal photopheresis has shown promising results and is indicated for a variety of conditions. The American Society for Apheresis currently recommends the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma, scleroderma, psoriasis, pemphigus vulgaris, atopic dermatitis, graft-versus-host disease, Crohn's disease, nephrogenic systemic fibrosis, and solid organ rejection in heart, lung, and liver transplantation. In this review, we aim to explore the proposed effects of extracorporeal photopheresis and to summarize published data on its use as a prophylactic and therapy in heart transplant rejection.
    MeSH term(s) Graft Rejection/etiology ; Graft Rejection/prevention & control ; Heart Transplantation/adverse effects ; Humans ; Lymphoma, T-Cell, Cutaneous ; Photopheresis ; Skin Neoplasms
    Language English
    Publishing date 2021-05-27
    Publishing country Denmark
    Document type Journal Article ; Review
    ZDB-ID 639001-8
    ISSN 1399-0012 ; 0902-0063
    ISSN (online) 1399-0012
    ISSN 0902-0063
    DOI 10.1111/ctr.14333
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top